Portfolio company
Artiva
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Artiva Biotherapeutics develops off-the-shelf natural killer cell therapies to treat patients with autoimmune diseases and cancers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Artiva Biotherapeutics
The company develops allogeneic natural killer cell therapies for patients with autoimmune diseases and cancer.
ARTV
This clinical-stage biotechnology company develops natural killer cell therapies for patients with autoimmune diseases and cancers.
Nkarta
This biopharmaceutical company develops engineered natural killer cell therapies to treat patients with cancer and autoimmune diseases.
Arcellx
This biotechnology company develops cell therapies to treat patients with cancer and autoimmune diseases.
Modulus Therapeutics
This company develops engineered NK-cell therapies for autoimmune disease patients using a generative design and rapid prototyping platform.
Orca Bio
This company develops high-precision allogeneic cell therapies to treat patients with blood cancers and autoimmune diseases by replacing diseased immune systems with donor cells.
Autolus Therapeutics
This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.
Allogene Therapeutics
The company develops off-the-shelf allogeneic CAR T-cell therapies for patients with blood cancers, solid tumours and autoimmune diseases.